Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELVN NASDAQ:MTSR NASDAQ:SWTX NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELVNEnliven Therapeutics$20.22+2.3%$20.67$13.30▼$30.03$1.17B0.93335,306 shs346,729 shsMTSRMetsera$31.14+2.8%$33.32$12.30▼$47.40$3.18BN/A1.45 million shs736,765 shsSWTXSpringWorks Therapeutics$46.99$46.90$28.21▼$62.00$3.54B0.682.66 million shsN/AVKTXViking Therapeutics$40.03-0.5%$31.10$18.92▼$81.73$4.52B0.674.64 million shs3.29 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELVNEnliven Therapeutics+2.28%+14.30%-5.78%+19.93%-7.25%MTSRMetsera+2.77%+2.43%-28.79%+5.49%+3,113,999,900.00%SWTXSpringWorks Therapeutics0.00%0.00%0.00%+1.91%+32.40%VKTXViking Therapeutics-0.52%+5.65%+26.56%+40.80%-31.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELVNEnliven Therapeutics2.9019 of 5 stars3.52.00.00.02.74.20.0MTSRMetseraN/AN/AN/AN/AN/AN/AN/AN/ASWTXSpringWorks TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AVKTXViking Therapeutics4.0858 of 5 stars3.51.00.04.73.52.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELVNEnliven Therapeutics 3.00Buy$41.20103.76% UpsideMTSRMetsera 3.00Buy$55.0076.62% UpsideSWTXSpringWorks Therapeutics 2.13Hold$52.5711.88% UpsideVKTXViking Therapeutics 3.00Buy$86.92117.14% UpsideCurrent Analyst Ratings BreakdownLatest ELVN, VKTX, MTSR, and SWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2025VKTXViking TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetStrong-Buy ➝ Strong-Buy$125.00 ➝ $122.007/24/2025VKTXViking TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$31.00 ➝ $38.007/2/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $48.006/25/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.006/20/2025MTSRMetseraWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$65.006/16/2025ELVNEnliven TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$40.00 ➝ $52.006/16/2025ELVNEnliven TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$37.006/10/2025MTSRMetseraGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$56.00 ➝ $62.005/16/2025ELVNEnliven TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $27.00(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELVNEnliven TherapeuticsN/AN/AN/AN/A$8.25 per shareN/AMTSRMetseraN/AN/AN/AN/A$4.28 per shareN/ASWTXSpringWorks Therapeutics$191.59M18.48N/AN/A$6.47 per share7.26VKTXViking TherapeuticsN/AN/AN/AN/A$7.07 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELVNEnliven Therapeutics-$89.02M-$1.92N/AN/AN/AN/A-29.15%-27.88%N/AMTSRMetsera-$209.13MN/A0.00∞N/AN/AN/AN/AN/ASWTXSpringWorks Therapeutics-$258.13M-$3.41N/AN/AN/A-115.60%-51.10%-43.80%N/AVKTXViking Therapeutics-$109.96M-$1.53N/AN/AN/AN/A-19.98%-19.38%10/22/2025 (Estimated)Latest ELVN, VKTX, MTSR, and SWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ELVNEnliven Therapeutics-$0.53-$0.49+$0.04-$0.49N/AN/A7/28/2025Q2 2025MTSRMetseraN/A-$0.66N/A-$0.66N/AN/A7/23/2025Q2 2025VKTXViking Therapeutics-$0.44-$0.58-$0.14-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELVNEnliven TherapeuticsN/AN/AN/AN/AN/AMTSRMetseraN/AN/AN/AN/AN/ASWTXSpringWorks TherapeuticsN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELVNEnliven TherapeuticsN/A21.0721.06MTSRMetseraN/A5.265.26SWTXSpringWorks TherapeuticsN/A4.334.18VKTXViking TherapeuticsN/A25.8625.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELVNEnliven Therapeutics95.08%MTSRMetseraN/ASWTXSpringWorks TherapeuticsN/AVKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipELVNEnliven Therapeutics25.90%MTSRMetseraN/ASWTXSpringWorks Therapeutics7.83%VKTXViking Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELVNEnliven Therapeutics5059.24 million36.36 millionOptionableMTSRMetsera81105.06 millionN/AN/ASWTXSpringWorks Therapeutics23075.35 million69.45 millionOptionableVKTXViking Therapeutics20112.45 million107.84 millionOptionableELVN, VKTX, MTSR, and SWTX HeadlinesRecent News About These CompaniesVirtu Financial LLC Sells 28,263 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)2 hours ago | marketbeat.comAigen Investment Management LP Purchases Shares of 13,780 Viking Therapeutics, Inc. (NASDAQ:VKTX)August 15 at 4:59 AM | marketbeat.comViking Therapeutics Earns Relative Strength Rating Upgrade; Hits Key BenchmarkAugust 14 at 10:36 PM | msn.comThe 3 Things That Matter for Viking Therapeutics NowAugust 13 at 4:10 AM | fool.comIf You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have TodayAugust 12, 2025 | msn.comConnor Clark & Lunn Investment Management Ltd. Purchases 222,293 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)August 12, 2025 | marketbeat.comTruist Financial Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)August 11, 2025 | theglobeandmail.comViking Therapeutics Concludes Broad Manufacturing Agreement With CordenPharma To Support Commercialization of VK2735August 11, 2025 | finance.yahoo.comNew Age Alpha Advisors LLC Buys New Stake in Viking Therapeutics, Inc. (NASDAQ:VKTX)August 9, 2025 | marketbeat.comRaiffeisen Bank International AG Buys 13,000 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)August 6, 2025 | marketbeat.comHarbour Investments Inc. Boosts Stake in Viking Therapeutics, Inc. (NASDAQ:VKTX)August 6, 2025 | marketbeat.comCetera Investment Advisers Raises Stock Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)August 5, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Buys Shares of 8,519 Viking Therapeutics, Inc. (NASDAQ:VKTX)August 5, 2025 | marketbeat.comViking Therapeutics (VKTX) Is Considered a Good Investment by Brokers: Is That True?August 4, 2025 | zacks.comNJ State Employees Deferred Compensation Plan Buys 10,000 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)August 4, 2025 | marketbeat.com2 Beaten-Down Stocks With Incredible Upside PotentialAugust 3, 2025 | fool.com2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top AnalystsAugust 3, 2025 | fool.comVictory Capital Management Inc. Has $317,000 Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)August 3, 2025 | marketbeat.comShort Interest in Viking Therapeutics, Inc. (NASDAQ:VKTX) Expands By 88,996.6%August 2, 2025 | marketbeat.comIs Viking Therapeutics the Next Big Biotech Bet?August 1, 2025 | fool.comAllianz Asset Management GmbH Sells 35,986 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)August 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeELVN, VKTX, MTSR, and SWTX Company DescriptionsEnliven Therapeutics NASDAQ:ELVN$20.22 +0.45 (+2.28%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$20.24 +0.02 (+0.10%) As of 08/15/2025 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Metsera NASDAQ:MTSR$31.14 +0.84 (+2.77%) As of 08/15/2025 04:00 PM EasternMetsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.SpringWorks Therapeutics NASDAQ:SWTXSpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.Viking Therapeutics NASDAQ:VKTX$40.03 -0.21 (-0.52%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$40.70 +0.67 (+1.67%) As of 08/15/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH Deere’s Sell-Off Could Be a Long-Term Buying Chance 3 Restaurant Stocks That Will Outperform in Q3 and Q4 Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore Arista Networks: Cashing In as the Tollbooth for AI Traffic Green Dot's 30% Rally: Turnaround Takes Off on Explosive Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access